Corea Therapeutics
Corea Therapeutics specializes in cancer immunotherapies and antibody-drug conjugates for the treatment of solid tumors. They have developed innovative technologies to generate NK cell-based targeted immunotherapies, with a platform that allows engineering of NK cells into targeted chemoimmunotherapy for various cancers. The company is open to partnerships and continues to expand its pipeline to a wide variety of solid tumors.
Industries
Nr. of Employees
small (1-50)
Products
NK cell–based targeted chemoimmunotherapy platform
A platform combining engineered NK cells with targeted therapeutic modalities to create chemoimmunotherapy approaches for solid tumors, with constructs described to target HER2-positive tumors.
NK cell–based targeted chemoimmunotherapy platform
A platform combining engineered NK cells with targeted therapeutic modalities to create chemoimmunotherapy approaches for solid tumors, with constructs described to target HER2-positive tumors.
Services
Engagements for research partnerships, licensing, or joint development using engineered NK cell and targeted chemoimmunotherapy technologies.
Engagements for research partnerships, licensing, or joint development using engineered NK cell and targeted chemoimmunotherapy technologies.
Expertise Areas
- Cancer immunotherapy
- Antibody-drug conjugates
- Natural killer (NK) cell therapies
- Targeted cellular chemoimmunotherapy
Key Technologies
- NK cell engineering
- Cell therapy platforms
- Antibody-drug conjugates
- Targeted chemoimmunotherapy